Katherine V. Houser

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito et al. · The Lancet · 2017 · 304 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

Martin R. Gaudinski, Emily E. Coates, Katherine V. Houser et al. · PLoS Medicine · 2018 · 253 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design

Chih‐Jen Wei, Jeffrey C. Boyington, Kaifan Dai et al. · Science Translational Medicine · 2010 · 233 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Katherine V. Houser, Grace Chen, Cristina Carter et al. · Nature Medicine · 2022 · 163 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses

Graeme E. Price, Mark R. Soboleski, Chia-Yun Lo et al. · Vaccine · 2009 · 130 citations

Veterinary Medicine, Immunology, Infectious Diseases +15